Condition: Hepatocellular Cancer · Squamous-Cell Non-Small Cell Lung Cancer · Sponsor: AbbVie
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABBV-324 is given to adult participants to treat hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period. Approximately 232 HCC or LUSC will be enrolled in the study in approximately 45 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of ABBV-324 until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will receive ABBV-324, or a comparator of oral lenvatinib. The study will run for a duration of approximately 6.5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center /ID# 270526 | Duarte, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120 | Irvine, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center /ID# 271573 | Los Angeles, California, United States | Recruiting |
| UC Irvine Medical Center /ID# 270507 | Orange, California, United States | Recruiting |
| UCLA - Santa Monica /ID# 275995 | Santa Monica, California, United States | Recruiting |
| University of Chicago Medical Center /ID# 270517 | Chicago, Illinois, United States | Recruiting |
| Washington University /ID# 275757 | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center /ID# 271228 | New York, New York, United States | Recruiting |
| Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269 | Philadelphia, Pennsylvania, United States | Recruiting |
| SCRI Oncology Partners /ID# 272750 | Nashville, Tennessee, United States | Recruiting |
| Nanfang Hospital - Southern Medical University /ID# 276916 | Guangzhou, Guangdong, China | Recruiting |
| Zhongshan Hospital Fudan University /ID# 276917 | Shanghai, Shanghai Municipality, China | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06858813